Thirty-fifth Patient Enrolled In The NeuroVasx CPAX Aneurysm

NeuroVasx, Inc. is developing its cPAX aneurysm Treatment System to meet the need for a better, more cost effective solution for the minimally invasive treatment of cerebral aneurysms. A cerebral aneurysm is an abnormal bulge or sac in the wall of an artery in the brain. If ruptured, the aneurysm can result in massive intracranial bleeding and often lead to death.

The NeuroVasx Clinical Study, based in South America, will be a critical component to the company's 510(k) Application to the FDA, which they intend to submit in early 2007. Eric Timko, President and CEO of NeuroVasx, Inc. stated, "The enrollment of the thirty-fifth patient in our clinical study is a major achievement for our team at NeuroVasx. It brings us one step closer to our 510(k) submission, a critical milestone for the company."

About NeuroVasx, Inc

NeuroVasx, Inc. (http://www.neurovasx.com) is a privately held medical device company located in Maple Grove, MN. The company is dedicated to the development and commercialization of technologies for the endovascular treatment of hemorrhagic and ischemic stroke.

NeuroVasx, Inc.
http://www.neurovasx.com
(责任编辑：泉水)

搜索

热门标签:

Thirty-fifth Patient Enrolled In The NeuroVasx CPAX Aneurysm